Cost-utility analyses in orthopaedic surgery

Journal of Bone and Joint Surgery

Volumn 87, Issue 6, 2005, Pages 1253-1259

  Brauer, Carmen A ^a   Rosen, Allison B ^b   Olchanski, Natalia V ^a   Neumann, Peter J ^a  

^a HARVARD CENTER FOR RISK ANALYSIS   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHROPLASTY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE ORGANIZATION; MEDICAL PRACTICE; ORTHOPEDICS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW;

EID: 19944397844     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.D.02152     Document Type: Review

References (57)

1. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53-72.
2. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54. www.hqlo.com/content/1/1/54.
3. Kaplan RM, Anderson JP A general health policy model: update and applications. Health Serv Res. 1988;23:203-35.
4. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1172-7.
5. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-41.
6. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276:1253-8.
7. Gold M. Panel on cost-effectiveness in health and medicine. Med Care. 1996:34(12 Suppl):DS197-9.
8. Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med. 2000; 132:964-72.
9. Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making. 2000;20:451-67.
10. Bell CM, Chapman RH, Stone PW, Sandberg EA, Neumann PJ. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making. 2001;21:288-94.
11. Office of Health Economics and the International Federation of Pharmaceutical Manufacturers' Associations. Health Economic Evaluations Database. www.ohe-heed.com. Accessed June 26, 2002.
12. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharma ceuticals cost-effective? A review of the evidence. Health Aff (Millwood). 2000; 19:92-109.
13. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;282:1453-7.
14. Gold MR, editor. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
15. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-81.
16. Daellenbach HG, Gillespie WJ, Crosbie P, Daellenbach US. Economic appraisal of new technology in the absence of survival data - the case of total hip replacement. Soc Sci Med. 1990;31:1287-93.
17. Gillespie WJ, Pekarsky B, O'Connell DL. Evaluation of new technologies for total hip replacement. Economic modelling and clinical trials. J Bone Joint Surg Br. 1995;77:528-33.
18. Faulkner A, Kennedy LG, Baxter K, Donovan J, Wilkinson M, Bevan G. Effectiveness of hip prostheses in primary total hip replacement: a critical review of evidence and an economic model. Health Technol Assess. 1998;2:1-133.
19. Fitzpatrick R. Shortall E, Sculpher M, Murray D, Morris R, Lodge M, Dawson J, Carr A. Britton A. Briggs A. Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses. Health Technol Assess. 1998;2:1-64.
20. Fry RN, Avey SG, Sullivan SD. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard - a Foundation for Managed Care Pharmacy Task Force report. Value Health. 2003;6:505-21.
21. Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsij PG, Littenberg B. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion. 1993;33:544-51.
22. Blackmore CC, Ramsey SD, Mann FA. Deyo RA. Cervical spine screening with CT in trauma patients: a cost-effectiveness analysis. Radiology. 1999; 212:117-25.
23. Brothers TE, Frank CE, Frank B, Robison JG, Elliott BM, Del Schutte H, Merrill KD, Friedman RJ. Is duplex venous surveillance worthwhile after arthroplasty? J Surg Res. 1997;67:72-8.
24. Bryan S, Parkin D, Donaldson C. Chiropody and the QALY: a case study in assigning categories of disability and distress to patients. Health Policy. 1991;18:169-85.
25. Chang RW, Pellisier JM, Hazen GB. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA. 1996;275:858-65.
26. Chung KC, Walters MR, Greenfield ML, Chernew ME. Endoscopic versus open carpal tunnel release: a cost-effectiveness analysis. Plast Reconstr Surg. 1998;102:1089-99.
27. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer. 1999;7:271-9.
28. Eckman MH, Greenfield S, Mackey WC, Wong JB, Kaplan S, Sullivan L, Dukes K, Pauker SG. Foot infections in diabetic patients. Decision and cost-effectiveness analyses. JAMA. 1995;273:712-20.
29. Fisman DN, Reilly DT, Karchmer AW, Goldie SJ. Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. Clin Infect Dis. 2001;32:419-30.
30. Garellick G, Malchau H, Herberts P, Hansson E, Axelsson H, Hansson T. Life expectancy and cost utility after total hip replacement. Clin Orthop Relat Res. 1998;346:141-51.
31. Geelhoed E, Harris A, Prince R. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health. 1994;18:153-60.
32. Givon U, Ginsberg GM, Horoszowski H, Shemer J. Cost-utility analysis of total hip arthroplasties. Technology assessment of surgical procedures by mailed questionnaires. Int J Technol Assess Health Care. 1998;14:735-42.
33. Gottlob CA, Baker CL Jr, Pellissier JM, Colvin L. Cost effectiveness of anterior cruciate ligament reconstruction in young adults. Clin Orthop Relat Res. 1999; 367:272-82.
34. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2000;18:72-9.
35. Jacobson JJ, Schweitzer SO, Kowalski CJ. Chemoprophylaxis of prosthetic joint patients during dental treatment: a decision-utility analysis. Oral Surg Oral Med Oral Pathol. 1991;72:167-77.
36. James M, St Leger S, Rowsell KV. Prioritising elective care: a cost utility analysis of orthopaedics in the north west of England. J Epidemiol Community Health. 1996;50:182-9.
37. Jonsson B, Kanis J, Dawson A, Oden A, Johnell O. Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int. 1999;10:193-9.
38. Jonsson B. Targeting high-risk populations. Osteoporos Int. 1998;8 Suppl 1:S13-6.
39. Jonsson B, Chnstiansen C, Johnell O, Hedbrandt J. Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int. 1995;5:136-42.
40. Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G. Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl. 1996;103:30-40.
41. Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B. Cost-effectiveness of preventing hip fracture in the general female population. Osteopors Int. 2001;12:356-61.
42. Keen JD, Keen RR. The cost-effectiveness of exclusion arteriography in extremity trauma. Cardiovasc Surg. 2001;9:441-7.
43. Keen JD, Dunne PM, Keen RR, Langer BG. Proximity arteriography: cost-effectiveness in asymptomatic penetrating extremity trauma. J Vase Interv Radiol. 2001;12:813-21.
44. Krijnen P, Kaandorp CJ, Steyerberg EW, van Schaardenburg D, Moens HJ, Habbema JD. Antibiotic prophylaxis for haematogenous bacterial arthritis in patients with joint disease: a cost effectiveness analysis. Ann Rheum Dis. 2001;60:359-66.
45. Kuntz KM, Snider RK, Weinstein JN, Pope MH, Katz JN. Cost-effectiveness of fusion with and without instrumentation for patients with degenerative spon-dylolisthesis and spinal stenosis. Spine. 2000;25:1132-9.
46. Launois R, Henry B, Marty JR, Gersberg M, Lassale C, Benoist M, Goehrs JM. Chemonucleolysis versus surgical discectomy for sciatica secondary to lumbar disc herniation. A cost and quality-of-life evaluation. Pharmacoeconomics. 1994; 6:453-63.
47. Lavernia CJ, Guzman JF, Gachupin-Garcia A. Cost effectiveness and quality of life in knee arthroplasty. Clin Orthop Relat Res. 1997;345:134-9.
48. Malter AD, Larson EB, Urban N, Deyo RA. Cost-effectiveness of lumbar discectomy for the treatment of herniated intervertebral disc. Spine. 1996;21: 1048-55.
49. Minas T. Chondrocyte implantation in the repair of chondral lesions of the knee: economics and quality of life. Am J Orthop. 1998;27:739-44.
50. Patrick DL, Ramsey SD, Spencer AC, Kinne S, Belza B, Topolski TD. Economic evaluation of aquatic exercise for persons with osteoarthritis. Med Care. 2001; 39:413-24.
51. Pickard JD, Bailey S, Sanderson H, Rees M, Garfield JS. Steps towards cost-benefit analysis of regional neurosurgical care. BMJ. 1990;301:629-35.
52. Seguin J, Garber BG, Coyle D, Hebert PC. An economic evaluation of trauma care in a Canadian lead trauma hospital. J Trauma. 1999;47(3 Suppl):S99-103.
53. Solomon DH, Kuntz KM. Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. Arthritis Rheum. 2000;43:1967-75.
54. Tosteson AN, Rosenthal DI, Melton LJ 3rd, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med. 1990;113:594-603.
55. Tsevat J, Durand-Zaleski I, Pauker SG. Cost-effectiveness of antibiotic prophylaxis for dental procedures in patients with artificial joints. Am J Public Health. 1989;79:739-43.
56. Willis M, Odegaard K, Persson U, Hedbrant J, Mellstrom D, Hammar M. A cost-effectiveness model of tibolone as treatment for the prevention of osteoporotic fractures in postmenopausal women in Sweden, Clin Drug Invest. 2001;21:115-27.
57. Laupacis A, Bourne R, Rorabeck C, Feeny D, Wong C, Tugwell P, Leslie K, Bullas R. Costs of elective total hip arthroplasty during the first year. Cemented versus noncemented. J Arthroplasty. 1994;9:481-7.